These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 19097496)
1. Prospective comparative evaluation of an office-based rapid immunological test with a Guaiac-based fecal occult blood test for colorectal cancer screening in general population with average-risk. Shastri YM; Loitsch S; Nowak R; Povse N; Stein J Clin Lab; 2008; 54(9-10):385-7. PubMed ID: 19097496 [No Abstract] [Full Text] [Related]
2. A 25-year follow-up of a population screened with faecal occult blood test in Finland. Malila N; Hakama M; Pukkala E Acta Oncol; 2007; 46(8):1103-6. PubMed ID: 17851857 [TBL] [Abstract][Full Text] [Related]
3. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer. Worthley DL; Smith A; Bampton PA; Cole SR; Young GP Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514 [TBL] [Abstract][Full Text] [Related]
4. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119 [TBL] [Abstract][Full Text] [Related]
5. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Smith A; Young GP; Cole SR; Bampton P Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938 [TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292 [TBL] [Abstract][Full Text] [Related]
7. Does use of the Coloscreen Self-Test improve patient compliance with fecal occult blood screening? Park SI; Saxe JC; Weesner RE Am J Gastroenterol; 1993 Sep; 88(9):1391-4. PubMed ID: 8362837 [TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Hoffman RM; Steel S; Yee EF; Massie L; Schrader RM; Murata GH Prev Med; 2010; 50(5-6):297-9. PubMed ID: 20307568 [TBL] [Abstract][Full Text] [Related]
9. Green-coloured results on guaiac-based faecal occult blood testing should be considered positive. Skitek M Ann Clin Biochem; 2005 May; 42(Pt 3):234-5; author reply 235. PubMed ID: 15949162 [No Abstract] [Full Text] [Related]
10. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589 [TBL] [Abstract][Full Text] [Related]
11. [Evidence-based planning: the case of mass screening for colorectal cancer in the Lazio region of Italy]. Federici A; Borgia P; Guasticchi G Ann Ig; 2005; 17(4):313-22. PubMed ID: 16156391 [TBL] [Abstract][Full Text] [Related]
12. The effect of fecal occult-blood screening on the incidence of colorectal cancer. Allison JE N Engl J Med; 2001 Mar; 344(13):1022; author reply 1023. PubMed ID: 11280326 [No Abstract] [Full Text] [Related]
13. A new immunological test strip device for the rapid, qualitative detection of faecal occult blood. Trojan J; Povse N; Schröder O; Stein J Z Gastroenterol; 2002 Nov; 40(11):921-4. PubMed ID: 12436369 [TBL] [Abstract][Full Text] [Related]
14. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Fletcher RH; Ransohoff DF; Imperiale TF Cancer; 2007 May; 109(9):1925-6; author reply 1926. PubMed ID: 17370313 [No Abstract] [Full Text] [Related]
15. Fecal occult blood testing: comparative evaluation of a two-hole versus a three-hole single slide test. Porschen R; Kruis W; Strohmeyer G Hepatogastroenterology; 1993 Apr; 40(2):191-3. PubMed ID: 8509054 [TBL] [Abstract][Full Text] [Related]
16. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy. Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918 [TBL] [Abstract][Full Text] [Related]
17. Fecal occult blood testing for colorectal cancer in an ethnically diverse population. Glober GA; Hundahl S; Stucke J; Choy M West J Med; 1994 Oct; 161(4):377-82. PubMed ID: 7817548 [TBL] [Abstract][Full Text] [Related]
18. Mass screening for colorectal cancer in Japan. Hisamichi S; Fukao A; Fujii Y; Tsuji I; Komatsu S; Inawashiro H; Tsubono Y Cancer Detect Prev; 1991; 15(5):351-6. PubMed ID: 1751945 [TBL] [Abstract][Full Text] [Related]
19. A system-based intervention to improve colorectal cancer screening uptake. Hoffman RM; Steel SR; Yee EF; Massie L; Schrader RM; Moffett ML; Murata GH Am J Manag Care; 2011 Jan; 17(1):49-55. PubMed ID: 21348568 [TBL] [Abstract][Full Text] [Related]
20. Experiences in providing a screening service for colorectal cancer from a pathology laboratory. Edwards JE; Williams JA; Thomas DW Pathology; 2004 Aug; 36(4):330-4. PubMed ID: 15370132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]